Fabienne Thomas

3.1k total citations
109 papers, 2.0k citations indexed

About

Fabienne Thomas is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Fabienne Thomas has authored 109 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 30 papers in Molecular Biology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Fabienne Thomas's work include Colorectal Cancer Treatments and Studies (22 papers), Cancer therapeutics and mechanisms (17 papers) and Pancreatic and Hepatic Oncology Research (13 papers). Fabienne Thomas is often cited by papers focused on Colorectal Cancer Treatments and Studies (22 papers), Cancer therapeutics and mechanisms (17 papers) and Pancreatic and Hepatic Oncology Research (13 papers). Fabienne Thomas collaborates with scholars based in France, United Kingdom and United States. Fabienne Thomas's co-authors include Étienne Chatelut, Isabelle Hennebelle, Jean‐Pierre Delord, Mélanie White‐Koning, Philippe Rochaix, A Gancel, Sylvie Quaranta, F. Catus, Ben Allal and Marie-Christine Étienne-Grimaldi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Journal of Clinical Oncology.

In The Last Decade

Fabienne Thomas

102 papers receiving 2.0k citations

Peers

Countries citing papers authored by Fabienne Thomas

Since Specialization

Citations

This map shows the geographic impact of Fabienne Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabienne Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabienne Thomas more than expected).

Fields of papers citing papers by Fabienne Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabienne Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabienne Thomas. The network helps show where Fabienne Thomas may publish in the future.

Co-authorship network of co-authors of Fabienne Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Fabienne Thomas. A scholar is included among the top collaborators of Fabienne Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabienne Thomas. Fabienne Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing thymidine phosphorylase 2024 ·Cancer Letters ·(unknown), Marie‐Hélène Laverrière, Maxime Henry, (unknown), (unknown), Cécile Arellano, (unknown), Fabienne Thomas, Véronique Josserand, Édouard Girard, Gaël S. Roth, Arnaud Millet	2
2	Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing 2024 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Étienne Chatelut, Marie-Christine Étienne-Grimaldi, Fabienne Thomas	1
3	Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis 2024 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Manon Launay, Laure Raymond, Jérôme Guitton, Marie‐Anne Loriot, Étienne Chatelut, Vincent Haufroid, Fabienne Thomas, Marie-Christine Etienne-Grimaldi	0
4	Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), Julia Gilhodes, (unknown), Bastien Cabarrou, (unknown), Thomas Filleron, (unknown), (unknown), V. Feillel, (unknown), (unknown), (unknown), (unknown), Fabienne Thomas, Laurence Gladieff, Christine Toulas	1
5	Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors? 2023 ·British Journal of Clinical Pharmacology ·(unknown), Xavier Fonrose, Fabienne Thomas, Gaël S. Roth, Emmanuelle Jacquet, (unknown), (unknown), (unknown), (unknown), Françoise Stanke‐Labesque, Elodie Gautier‐Veyret	5
6	Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency 2022 ·British Journal of Clinical Pharmacology ·(unknown), Manon Launay, Bernard Royer, Jérôme Guitton, Elodie Gautier‐Veyret, Sophie Broutin, Camille Tron, (unknown), Joseph Ciccolini, Damien Richard, (unknown), Vincent Haufroid, (unknown), Antonin Schmitt, Marie-Christine Étienne-Grimaldi, Céline Narjoz, Fabienne Thomas, (unknown)	15
7	Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury 2022 ·Metabolites ·(unknown), Cécile Arellano, Christelle Vachoux, Christine Chevreau, Nicolas J. Cabaton, Frédéric Pont, Nathalie Saint‐Laurent, Thierry Lafont, Étienne Chatelut, Fabienne Thomas	3
8	Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency 2022 ·European Journal of Cancer ·Marie-Christine Étienne-Grimaldi, Nicolas Pallet, Valérie Boige, Joseph Ciccolini, Laurent Chouchana, Chantal Barin‐Le Guellec, Aziz Zaanan, Céline Narjoz, Julien Taı̈eb, Fabienne Thomas, Marie‐Anne Loriot	19
9	Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr 2021 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Florent Puisset, Fabienne Thomas, Étienne Chatelut, Mélanie White‐Koning	24
10	Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines 2021 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), Mony Ung, (unknown), (unknown), Marion Montastruc, Florent Puisset, Fabienne Thomas	3
11	Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation 2021 ·Annals of Oncology ·Fabienne Thomas, (unknown), Manon Launay, Camille Tron, Marie-Christine Étienne-Grimaldi, Elodie Gautier‐Veyret, Vincent Haufroid, Nicolas Pallet, Bernard Royer, Céline Narjoz, Antonin Schmitt	11
12	Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study 2021 ·Pharmaceuticals ·(unknown), Nihel Khoudour, (unknown), Dorothée Lebert, (unknown), Fabienne Thomas, David Ternant, Bruno Lacarelle, Jérôme Guitton, Joseph Ciccolini, Benoı̂t Blanchet	19
13	Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data 2021 ·Pharmaceuticals ·(unknown), (unknown), Fabienne Thomas, Mélanie White‐Koning, Ben Allal, Caroline Protin, Loïc Ysebaert, Étienne Chatelut, Florent Puisset	4
14	Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma 2020 ·Cancers ·(unknown), Christine Chevreau, (unknown), (unknown), Caroline Delmas, (unknown), Jean‐Yves Blay, Didier Cupissol, Emmanuelle Bompas, Antoîne Italiano, Nicolás Isambert, (unknown), Nicolas Penel, François Bertucci, Cécile Guillemet, (unknown), Stéphanie Foulon, Étienne Chatelut, Axel Le Cesne, Fabienne Thomas	3
15	Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients 2019 ·British Journal of Clinical Pharmacology ·(unknown), Catherine Alix‐Panabières, Thierry Lafont, Ben Allal, R. Garrel, Laurence Digue, J. Guigay, Didier Cupissol, Jean‐Pierre Delord, Benjamin Lallemant, M. Alfonsi, Karine Aubry, Martine Mazel, François Bécher, (unknown), Étienne Chatelut, Fabienne Thomas	19
16	Intérêts et limites de la recherche du déficit en dihydropyrimidine déshydrogénase dans le suivi des patients traités par fluoropyrimidines : résultats de deux enquêtes nationales de pratiques réalisées auprès des médecins et des biologistes 2019 ·Bulletin du Cancer ·Marie‐Anne Loriot, (unknown), (unknown), Karine Le Malicot, Jean‐François Seitz, Pierre Michel, Jean-Louis Legoux, Olivier Bouché, Thierry André, Roger Faroux, Suzette Delaloge, David Malka, J. Guigay, Juliette Thariat, Fabienne Thomas, Chantal Barin‐Le Guellec, Joseph Ciccolini, Jean-Christophe Boyer, Marie-Christine Étienne-Grimaldi	3
17	Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report 2018 ·Cancer Chemotherapy and Pharmacology ·Fabienne Thomas, Gareth J. Veal, Souleiman El Balkhi, Thierry Lafont, Nicolas Picard, Laurence Brugières, Étienne Chatelut, Christophe Piguet	7
18	Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase <em>(DPYD)</em> gene 2018 ·Cancer Management and Research ·Xandra García‐González, Sara López‐Tarruella, María I. García, Eva González-Haba, (unknown), (unknown), Yolanda Jerez, Fabienne Thomas, (unknown), (unknown), Miguel Martín, Luis A. López‐Fernández	5
19	Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study 2017 ·Clinical Cancer Research ·(unknown), Christine Chevreau, Sophie Broutin, Jérôme Guitton, Bénédicte Lelièvre, Joseph Ciccolini, (unknown), Aude Fléchon, R. Delva, Gwénaëlle Gravis, Jean‐Pierre Lotz, Jacques‐Olivier Bay, Marine Gross‐Goupil, Angélo Paci, (unknown), (unknown), Étienne Chatelut, Fabienne Thomas	14
20	Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro- D -glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer 2010 ·Clinical Cancer Research ·S. Vergèz, Jean‐Pierre Delord, Fabienne Thomas, Philippe Rochaix, (unknown), Thomas Filleron, (unknown), Pierre Canal, F. Courbon, Ben Allal	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact